1. Home
  2. LEGN vs IESC Comparison

LEGN vs IESC Comparison

Compare LEGN & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • IESC
  • Stock Information
  • Founded
  • LEGN 2014
  • IESC 1997
  • Country
  • LEGN United States
  • IESC United States
  • Employees
  • LEGN N/A
  • IESC N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • IESC Engineering & Construction
  • Sector
  • LEGN Health Care
  • IESC Industrials
  • Exchange
  • LEGN Nasdaq
  • IESC Nasdaq
  • Market Cap
  • LEGN 6.0B
  • IESC 5.4B
  • IPO Year
  • LEGN 2020
  • IESC 1998
  • Fundamental
  • Price
  • LEGN $32.66
  • IESC $256.69
  • Analyst Decision
  • LEGN Strong Buy
  • IESC
  • Analyst Count
  • LEGN 13
  • IESC 0
  • Target Price
  • LEGN $80.62
  • IESC N/A
  • AVG Volume (30 Days)
  • LEGN 1.3M
  • IESC 169.5K
  • Earning Date
  • LEGN 03-10-2025
  • IESC 01-31-2025
  • Dividend Yield
  • LEGN N/A
  • IESC N/A
  • EPS Growth
  • LEGN N/A
  • IESC 117.84
  • EPS
  • LEGN N/A
  • IESC 9.89
  • Revenue
  • LEGN $520,183,000.00
  • IESC $2,884,358,000.00
  • Revenue This Year
  • LEGN $120.36
  • IESC N/A
  • Revenue Next Year
  • LEGN $67.91
  • IESC N/A
  • P/E Ratio
  • LEGN N/A
  • IESC $25.95
  • Revenue Growth
  • LEGN 122.96
  • IESC 21.33
  • 52 Week Low
  • LEGN $30.17
  • IESC $80.86
  • 52 Week High
  • LEGN $70.13
  • IESC $320.08
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.28
  • IESC 60.06
  • Support Level
  • LEGN $30.17
  • IESC $213.00
  • Resistance Level
  • LEGN $37.92
  • IESC $224.40
  • Average True Range (ATR)
  • LEGN 2.07
  • IESC 12.12
  • MACD
  • LEGN 0.12
  • IESC 6.14
  • Stochastic Oscillator
  • LEGN 32.13
  • IESC 91.98

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About IESC IES Holdings Inc.

IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.

Share on Social Networks: